DelveInsight’s, “Glaucoma Pipeline Insight 2023,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in the Glaucoma pipeline landscape. It covers the Glaucoma pipeline drug profiles, including Glaucoma clinical and nonclinical stage products. It also covers the Glaucoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Glaucoma Emerging drugs, the Glaucoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Glaucoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Glaucoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Glaucoma clinical trials studies, Glaucoma NDA approvals (if any), and product development activities comprising the technology, Glaucoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Glaucoma Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Glaucoma Pipeline landscape @ Glaucoma Pipeline Outlook Report
Glaucoma Overview
Glaucoma is a group of eye diseases causing optic nerve damage. The optic nerve carries images from the retina, which is the specialized light sensing tissue, to the brain so we can see. In glaucoma, eye pressure plays a role in damaging the delicate nerve fibers of the optic nerve. When a significant number of nerve fibers are damaged, blind spots develop in the field of vision. Once nerve damage and visual loss occur, it is permanent. Most people don’t notice these blind areas until much of the optic nerve damage has already occurred.
Recent Developmental Activities in the Glaucoma Treatment Landscape
For further information, refer to the detailed Glaucoma Drugs Launch, Glaucoma Developmental Activities, and Glaucoma News, click here for Glaucoma Ongoing Clinical Trial Analysis
Glaucoma Emerging Drugs Profile
QLS-101 is our lead program based upon research from the laboratory of Professor Michael Fautsch at Mayo Clinic. The original compounds were first synthesized at the laboratory of Professor Peter Dosa at the University of Minnesota. QLS-101 is a novel prodrug of a well-characterized ATP-sensitive potassium (KATP) channel modulator that lowers intraocular pressure (IOP) by relaxing vessels of the vascular and vascular-like tissues distal to the Trabecular Meshwork, thereby reducing distal outflow resistance and lowering Episcleral Venous Pressure (EVP). QLS-101 has shown efficacy in lowering IOP across multiple preclinical animal species, including mice, rabbits, dogs, and non-human primates, as well as in human eye explants. To date, QLS-101 has been demonstrated to be well-tolerated with no observed hyperemia in the efficacious dose range. Qlaris Bio has initiated clinical studies with QLS-101 in patients with Primary Open Angle Glaucoma, Ocular Hypertension, Normal Tension Glaucoma, and Sturge-Weber syndrome.
NCX 470 is a novel, potential best-in-class, nitric oxide (NO)-donating prostaglandin analog eye drop, designed to release bimatoprost and NO into the eye to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small naturally-occurring signaling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). Bimatoprost, marketed under the brand name LUMIGAN® by AbbVie, Inc., is one of the leading branded products in the class of prostaglandin analogs (PGAs). Prostaglandin analogs are the most widely used class of drugs for IOP-lowering in patients with open-angle glaucoma or ocular hypertension. Nitric oxide brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action than that engaged by prostaglandin analogs. We believe a novel dual mechanism of action can achieve superior IOP-lowering compared to the parent compound alone. NCX 470 has the same mechanism-of-action as our first marketed product in the U.S. NCX 470 is currently in two multi-regional Phase 3 clinical trials, Mont Blanc and Denali, evaluating the IOP lowering efficacy of once-daily dosed NCX 470 ophthalmic solution 0.1% compared to latanoprost ophthalmic solution 0.005% in patients with open-angle glaucoma or ocular hypertension. Latanoprost, first marketed as Xalatan, is the most prescribed PGA in the U.S.
Glaucoma Therapeutics Assessment
There are approx. 70+ key companies which are developing the therapies for Glaucoma. The companies which have their Glaucoma drug candidates in the most advanced stage, i.e. phase III include, Nicox.
Find out more about the Glaucoma Pipeline Segmentation, Therapeutics Assessment, and Glaucoma Emerging Drugs @ Glaucoma Treatment Landscape
Scope of the Glaucoma Pipeline Report
Dive deep into rich insights for drugs for Glaucoma Pipeline Companies and Therapies, click here @ Glaucoma Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Glaucoma Mergers and acquisitions, Glaucoma Licensing Activities @ Glaucoma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/